GFAP and tauopathy: More recently, new biomarkers are increasingly being validated, including blood-based biomarkers such as pTau 217 and pTau213 for tauopathy, neurofilament light chain (NfL) for neuronal injury, and glial fibrillary acidic protein (GFAP) for neuroinflammation.7